Ethosuximide Capsules

Pfizer Inc

Revision date : 2012-06-13

SDS Library

Move your SDS library online today

Check Icon
Setup – Easy setup with our database of 16 million+ SDSs
Check Icon
Up-to-date – Your SDS get updated to latest versions.
Check Icon
Employee access – Tablets, Smartphones, or link from Corporate Intranet
Check Icon
Safety – One-click access to first aid information.
Check Icon
Labels – Generate Secondary Container Labels with just one click.
GHS07 GHS08
Health risk rating 5
Safety risk rating 1
Environmental risk rating 1

Note: Ingredients listed on restricted chemical lists

EC/CAS

200-289-5/56-81-5

Name of the chemical

glycerol

Concentration

*

EC/CAS

25322-68-3

Name of the chemical

polyethyleneglycol

Concentration

*

EC/CAS

232-554-6/9000-70-8

Name of the chemical

gelatin

Concentration

*

EC/CAS

8004-92-0

Name of the chemical

1H-Indene-1,3(2H)-dione, 2-(2-quinolinyl)-, sulfonated, sodium salts (CI 47005) (35), (36)

Concentration

*

EC/CAS

240-474-8

Name of the chemical

Disodium 2-(2,4,5,7-tetraiodo-6-oxido-3-oxoxanthen-9-yl)benzoate and its insoluble barium, strontium and zirconium lakes, salts and pigments

Concentration

*

General Information

Version

2.0

Revision date

2012-06-13

Product name

Ethosuximide Capsules

Product name

Ethosuximide Capsules

Identification on the label/Trade name

Zarontin

Chemical name

Mixture

1.2.1 Relevant identified uses

Pharmaceutical product used as anticonvulsant

Emergency telephone

1-800-424-9300, +1-703-527-3887

Icons in SDS

M004 M009 M010 M011 M017 GHS07 GHS08

Company Information

company name

Pfizer Inc

e-mail address of the competent person responsible for the Safety Data Sheet

pfizer-MSDS@pfizer.com

GHS Information

Signal word

DANGER

Hazard Codes

Hazard statements (CLP)

H303, H341, H360D

Hazard statements

Code

Statements

H303

May be harmful if swallowed

Section 2

SECTION 2: Hazards identification

Appearance Orange capsules

Signal word

DANGER

Hazard statements

May be harmful if swallowed. May damage the unborn child. Suspected of causing genetic defects.

Additional information

Short Term May be harmful if swallowed. (based on animal data) . Known Clinical Effects Effects reported during clinical use included vomiting and diarrhea. Central nervous system effects such as dizziness, headache, insomnia, irritability and weakness have also been reported. Clinical use of this drug has caused decreased blood cell count, increased eosinophils in blood or tissue (eosinophilia), skin rash, Stevens Johnson Syndrome (epidermal necrosis and exfoliative dermatitis). May cause adverse effects on the developing fetus. EU Indication of danger Harmful Toxic to Reproduction: Category 2 Mutagenic: Category 3 EU Hazard Symbols EU Risk Phrases R22 - Harmful if swallowed. R61 - May cause harm to the unborn child. R68 - Possible risk of irreversible effects. Australian Hazard Classification (NOHSC): Note

Hazardous Ingredients

Non-Dangerous Goods This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

SDS Library

Move your SDS library online today

Check Icon
Setup – Easy setup with our database of 16 million+ SDSs
Check Icon
Up-to-date – Your SDS get updated to latest versions.
Check Icon
Employee access – Tablets, Smartphones, or link from Corporate Intranet
Check Icon
Safety – One-click access to first aid information.
Check Icon
Labels – Generate Secondary Container Labels with just one click.